Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical study evaluating HLX26 in combination with Serplulimab and chemotherapy in previously untreated advanced non-small cell lung cancer (Stage IV).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HLX26 (anti-LAG-3 monoclonal antibody)
• Serplulimab (serplulimab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: NSCLC Stage IV | Phase 2 | Status: ACTIVE_NOT_RECRUITING